ONCT
Oncternal Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.56M
P/E Ratio
—
EPS
$-11.69
Beta
1.33
52W High
$0.53
52W Low
$0.53
50-Day MA
$0.53
200-Day MA
$1.55
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of cancer therapies for cancers with critical unmet medical needs. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $2.16M |
| Gross Profit (TTM) | $-6.51M |
| EBITDA | — |
| Operating Margin | -1757.00% |
| Return on Equity | -149.90% |
| Return on Assets | -76.40% |
| Revenue/Share (TTM) | $0.73 |
| Book Value | $3.09 |
| Price-to-Book | 0.17 |
| Price-to-Sales (TTM) | 0.72 |
| EV/Revenue | 0.853 |
| EV/EBITDA | 0.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 176.00% |
| Shares Outstanding | $2.96M |
| Float | $2.71M |
| % Insiders | 9.23% |
| % Institutions | 12.07% |
Data last updated: 4/9/2026